155 related articles for article (PubMed ID: 31851428)
1. Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study.
Takemoto S; Fukuda M; Yamaguchi H; Ikeda T; Akagi K; Tomono H; Umeyama Y; Dotsu Y; Taniguchi H; Gyotoku H; Senju H; Kitazaki T; Nakatomi K; Nagashima S; Fukuda M; Kinoshita A; Soda H; Mukae H
Thorac Cancer; 2020 Feb; 11(2):389-393. PubMed ID: 31851428
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature.
Mori R; Fujimoto D; Ito M; Tomii K
Oncotarget; 2017 Jul; 8(29):48521-48524. PubMed ID: 28591698
[TBL] [Abstract][Full Text] [Related]
4. Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
Tamiya M; Tamiya A; Yamadori T; Nakao K; Asami K; Yasue T; Otsuka T; Shiroyama T; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Kawase I; Hirashima T
Med Oncol; 2013; 30(3):676. PubMed ID: 23925664
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.
Kitamura K; Kubota K; Ando M; Takahashi S; Nishijima N; Sugano T; Toyokawa M; Miwa K; Kosaihira S; Noro R; Minegishi Y; Seike M; Yoshimura A; Gemma A
Cancer Chemother Pharmacol; 2013 Feb; 71(2):457-61. PubMed ID: 23178954
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
[TBL] [Abstract][Full Text] [Related]
7. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
[TBL] [Abstract][Full Text] [Related]
9. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
[TBL] [Abstract][Full Text] [Related]
10. Effect of medical thoracoscopy-guided intrapleural docetaxel therapy to manage malignant pleural effusion in patients with non-small cell lung cancer: A pilot study.
Choi MG; Park S; Oh DK; Kim HR; Lee GD; Lee JC; Choi CM; Ji W
Thorac Cancer; 2019 Oct; 10(10):1885-1892. PubMed ID: 31389192
[TBL] [Abstract][Full Text] [Related]
11. Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study.
Kasahara N; Sunaga N; Kuwako T; Naruse I; Imai H; Jingu A; Tsukagoshi Y; Masuda T; Kitahara S; Tsurumaki H; Yatomi M; Hara K; Koga Y; Sakurai R; Mori K; Kaira K; Maeno T; Asao T; Hisada T
Support Care Cancer; 2020 Oct; 28(10):4825-4831. PubMed ID: 31982960
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).
Hata A; Katakami N; Shimokawa M; Mitsudomi T; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2018 Nov; 19(6):e865-e869. PubMed ID: 30206044
[TBL] [Abstract][Full Text] [Related]
13. Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
Katayama Y; Yamada T; Sawada R; Kawachi H; Morimoto K; Watanabe S; Watanabe K; Takeda T; Chihara Y; Shiotsu S; Hibino M; Harada T; Nishioka N; Iwasaku M; Tokuda S; Takayama K
Oncologist; 2024 May; 29(5):e681-e689. PubMed ID: 38241181
[TBL] [Abstract][Full Text] [Related]
14. Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non-small cell lung cancer with brain metastasis.
Tanimura K; Uchino J; Tamiya N; Kaneko Y; Yamada T; Yoshimura K; Takayama K
Medicine (Baltimore); 2018 Jun; 97(23):e11084. PubMed ID: 29879079
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
[TBL] [Abstract][Full Text] [Related]
17. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer.
Nie K; Zhang Z; You Y; Zhuang X; Zhang C; Ji Y
Thorac Cancer; 2020 Jan; 11(1):8-14. PubMed ID: 31726490
[TBL] [Abstract][Full Text] [Related]
18. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients.
Shiono A; Kaira K; Mouri A; Yamaguchi O; Hashimoto K; Uchida T; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
Thorac Cancer; 2019 Apr; 10(4):775-781. PubMed ID: 30809973
[TBL] [Abstract][Full Text] [Related]
19. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain SA; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Bedke J; Gakis G; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Garcia Del Muro X; Rodriguez-Vida A; Cicin I; Harputluoglu H; Tagawa ST; Vaishampayan U; Aragon-Ching JB; Hamid O; Liepa AM; Wijayawardana S; Russo F; Walgren RA; Zimmermann AH; Hozak RR; Bell-McGuinn KM; Powles T;
Lancet Oncol; 2020 Jan; 21(1):105-120. PubMed ID: 31753727
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]